Combination, Rotational, and Sequential Therapy

Therapy of Moderate-to-Severe Psoriasis, Second Edition, Revised and Expanded

Volumn , Issue , 2003, Pages 179-196

  Lebwohl, Mark ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 20444436060     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b14220-12     Document Type: Chapter

References (73)

1. Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993;28(3):454–459.
2. Menter MA, See JA, Amend WJ, Ellis CN, Krueger GG, Lebwohl M, Morison WL, Prystowsky JH, Roenigk HH Jr, Shupack JL, Silverman AK, Weinstein GD, Yocum DE, Zanolli MD. Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7–9, 1994. J Am Acad Dermatol. 1996;34(2 Pt 1):315–21.
3. Koo J. Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad Dermatol. 1999;41(3 Pt 2):S25–8.
4. Schulze HJ, Steigleder GK. [Experiences in half-side treatment with tar additive to cignolin-salicylic-acid-white-vaseline therapy of psoriasis vulgaris] Z Hautkr. 1984;9(10):654–6.
5. Schulze HJ, Steigleder GK, Pullmann H, Bloedhorn H. [The effect of a tar admixture to dithranol-salicylic-acid-white-petrolatum therapy on the cytokinetics of psoriasis] Z Hautkr. 1984;59(5):288–90, 295–7.
6. Steigleder GK, Schulze HJ. [A new Cologne therapy scheme—addition of tar to cignoline-salicylic acid-white vaseline therapy in psoriasis vulgaris] Z Hautkr. 1984;59(3):188, 191-2.
7. Muller R, Naumann E, Detmar M, Orfanos CE. [Stability of cignolin (dithranol) in ointments containing tar with and without the addition of salicylic acid. Oxidation to danthron and dithranol dimer] Hautarzt. 1987; 38(2):107–11.
8. Patel B, Siskin S, Krazmien R, Lebwohl M. Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol. 1998;38(6 Pt 1):1010–1.
9. Lebwohl M, Siskin SB, Epinette W, Breneman D, Funicella T, Kalb R, Moore J. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol. 1996;35(2 Pt 1):268–9.
10. Lebwohl M, Yoles A, Lombardi K, Lou W. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol. 1998;39(3):447–50.
11. Hecker D, Worsley J, Yueh G, Lebwohl M. In vitro compatibility of tazarotene with other topical treatments of psoriasis. J Am Acad Dermatol. 2000;42(6): 1008–11.
12. Lebwohl M, Lombardi K, Tan MH. Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments. Int J Dermatol. 2001;40(1): 64–6.
13. Lebwohl MG, Breneman DL, Goffe BS, Grossman JR, Ling MR, Milbauer J, Pincus SH, Sibbald RG, Swinyer LJ, Weinstein GD, Lew-Kaya DA, Lue JC, Gibson JR, Sefton J. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol. 1998;39(4 Pt 1):590–6.
14. Lebwohl M, Martinez J, Weber P, DeLuca R. Effects of topical preparations on the erythemogenicity of UVB: implications forpsoriasis phototherapy. J Am Acad Dermatol. 1995;32(3):469–71.
15. Lebwohl M, Hecker D, Martinez J, Sapadin A, Patel B. Interactions between calcipotriene and ultraviolet light. J Am Acad Dermatol. 1997;37(1):93–5.
16. Lebwohl M, Quijije J, Gilliard J, Rollin T, Watts O. Interactions between ultraviolet light and topical calcitriol (submitted).
17. Diette KM, Gange RW, Stern RS, Arndt KA, Parrish JA. Coal tar phototoxicity: characteristics of the smarting reaction. J Invest Dermatol. 1985;84(4):268–71.
18. Hecker D, Worsley J, Yueh G, Kuroda K, Lebwohl M. Interactions between tazarotene and ultraviolet light. J Am Acad Dermatol. 1999;41(6):927–30.
19. Koo JY, Lowe NJ, Lew-Kaya DA, Vasilopoulos AI, Lue JC, Sefton J, Gibson JR. Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol. 2000 Nov;43(5 Pt 1):821–8.
20. Schiener R, Behrens-Williams SC, Pillekamp H, Kaskel P, Peter RU, Kerscher M. Calcipotriol vs. tazarotene as combination therapy with narrowband ultraviolet B(311 nm): efficacy in patients with severe psoriasis. Br J Dermatol. 2000;143(6):1275–8.
21. Brands S, Brakman M, Bos JD, de Rie MA. No additional effect of calcipotriol ointment on low-dose narrow-band UVB phototherapy in psoriasis. J Am Acad Dermatol. 1999;41(6):991–5.
22. Hecker D, Lebwohl M. Topical calcipotriene in combination with UVB phototherapy for psoriasis. Int J Dermatol. 1997;36(4):302–3.
23. Molin L. Topical calcipotriol combined with phototherapy for psoriasis. The results of two randomized trials and a review of the literature. Calcipotriol-UVB Study Group Dermatology. 1999;198(4):375–81.
24. Kokelj F, Lavaroni G, Guadagnini A. UVB versus UVB plus calcipotriol (MC 903) therapy for psoriasis vulgaris. Acta Derm Venereol. 1995;75(5):386–7.
25. Kragballe K. Combination of topical calcipotriol (MC 903) and UVB radiation for psoriasis vulgaris. Dermatologica. 1990;181(3):211–4.
26. Ramsay CA, Schwartz BE, Lowson D, Papp K, Bolduc A, Gilbert M. Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatic combination treatment. The Canadian Calcipotriol and UVB Study Group. Dermatology. 2000;200(1):17–24.
27. Speight EL, Farr PM. Calcipotriol improves the response of psoriasis to PUVA. Br J Dermatol. 1994;130(1):79–82.
28. Behrens S, Grundmann-Kollmann M, Peter RU, Kerscher M. Combination treatment of psoriasis with photochemotherapy and tazarotene gel, a receptorselective topical retinoid. Br J Dermatol. 1999;141(1):177.
29. Dover JS, McEvoy MT, Rosen CF, Arndt KA, Stern RS. Are topical corticosteroids useful in phototherapy for psoriasis? J Am Acad Dermatol. 1989; 20(5 Pt 1):748–54.
30. Horwitz SN, Johnson RA, Sefton J, Frost P. Addition of a topically applied corticosteroid to a modified Goeckerman regimen for treatment of psoriasis: effect on duration of remission. J Am Acad Dermatol. 1985;13(5 Pt 1):784–91.
31. Petrozzi JW. Topical steroids and UV radiation in psoriasis. Arch Dermatol. 1983;119(3):207–10.
32. LeVine MJ, Parrish JA. The effect of topical fluocinonide ointment on phototherapy of psoriasis. J Invest Dermatol. 1982;78(2):157–9.
33. Hanke CW, Steck WD, Roenigk HH Jr. Combination therapy for psoriasis. Psoralens plus long-wave ultraviolet radiation with betamethasone valerate. Arch Dermatol. 1979;115(9):1074–7.
34. Schmoll M, Henseler T, Christophers E. Evaluation of PUVA, topical corticosteroids and the combination of both in the treatment of psoriasis. Br J Dermatol. 1978;99(6):693–702.
35. Gould PW, Wilson L. Psoriasis treated with clobetasol propionate and photochemotherapy. Br J Dermatol. 1978;98(2):133–6.
36. Stern RS, Laird N, Melski J, Parrish JA, Fitzpatrick TB, Bleich HL. Cutaneous squamous-cell carcinoma in patients treated with PUVA. N Engl J Med. 1984; 310(18):1156–61.
37. Larko O, Swanbeck G. Is UVB treatment of psoriasis safe? A study of extensively UVB-treated psoriasis patients compared with a matched control group. Acta Derm Venereol. 1982;62(6):507–12.
38. Pittelkow MR, Perry HO, Muller SA, Maughan WZ, O’Brien PC. Skin cancer in patients with psoriasis treated with coal tar. A 25-year follow-up study. Arch Dermatol. 1981;117(8):465–8.
39. Ruzicka T, Sommerburg C, Braun-Falco O, Koster W, Lengen W, Lensing W, Letzel H, Meigel WN, Paul E, Przybilla B, et al. Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis. Arch Dermatol. 1990;126(4):482–6.
40. Orfanos CE, Steigleder GK, Pullmann H, Bloch PH. Oral retinoid and UVB radiation: a new, alternative treatment for psoriasis on an out-patient basis. Acta Derm Venereol. 1979;59(3):241–4.
41. Halasz CL. Narrowband UVB phototherapy for psoriasis: results with fixed increments by skintype (as opposed to percentage increments). Photodermatol Photoimmunol Photomed. 1999;15(2):81–4.
42. Tanew A, Guggenbichler A, Honigsmann H, Geiger JM, Fritsch P. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol. 1991;25(4): 682–4.
43. Anstey A, Hawk JL. Isotretinoin-PUVA in women with psoriasis. Br J Dermatol. 1997;136(5):798–9.
44. Paul BS, Momtaz K, Stern RS, Arndt KA, Parrish JA. Combined methotrexate– ultraviolet B therapy in the treatment of psoriasis. J Am Acad Dermatol. 1982;7(6):758–62.
45. Morison WL, Momtaz K, Parrish JA, Fitzpatrick TB. Combined methotrexate-PUVA therapy in the treatment of psoriasis. J Am Acad Dermatol. 1982; 6(1):46–51.
46. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy follow-up study. Cancer. 1994 Jun 1;73(11):2759–64.
47. Frezza EE, Fung JJ, van Thiel DH. Non-lymphoid cancer after liver transplantation. Hepatogastroenterology. 1997;44(16):1172–81.
48. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet. 2001;358(9287):1042–5.
49. Korstanje MJ, Hulsmans RF. Combination therapy cyclosporin A—PUVA in psoriasis. Acta Derm Venereol. 1990;70(1);89–90.
50. Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol. 2001;45(6): 953–6.
51. Sauer GC. Combined methotrexate and hydroxyurea therapy for psoriasis. Arch Dermatol. 1973;107(3):369–70.
52. Islam MN, Alam MN, Haq SA, Moyenuzzaman M, Patwary MI, Rahman MH. Efficacy of sulphasalazine plus methotrexate in rheumatoid arthritis. Bangladesh Med Res Counc Bull. 2000;26(1):1–7.
53. Allegue Rodriguez F, Sendagorta Gomendio E, Freire Murgueytio P, Moreno Izquierdo R, Ledo Pozueta A. [Treatment of erythrodermic and pustulous psoriasis with a combination of methotrexate and etretinate] Med Cutan Ibero Lat Am. 1988;16(1):43–9.
54. Rosenbaum MM, Roenigk HH Jr. Treatment of generalized pustular psoriasis with etretinate (Ro 10-9359) and methotrexate. J Am Acad Dermatol. 1984; 10(2 Pt 2):357–61.
55. Tuyp E, MacKie RM. Combination therapy for psoriasis with methotrexate and etretinate. J Am Acad Dermatol. 1986;14(1):70–3.
56. Larsen FG, Nielsen-Kudsk F, Jakobsen P, Schroder H, Kragballe K. Interaction of etretinate with methotrexate pharmacokinetics in psoriatic patients. J Clin Pharmacol. 1990;30(9):802–7.
57. van de Kerkhof PC, de Rooij MJ. Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporin treatment: response to long-term acitretin maintenance. Br J Dermatol. 1997; 136(2):275–8.
58. Salomon D, Mesheit J, Masgrau-Peya E, Feldmann R, Saurat JH. Acitretin does not prevent psoriasis relapse related to cyclosporin A tapering. Br J Dermatol. 1994;130(2):257–8.
59. Kuijpers AL, van Dooren-Greebe JV, van de Kerkhof PC. Failure of combination therapy with acitretin and cyclosporin A in 3 patients with erythrodermic psoriasis. Dermatology. 1997;194(1):88–90.
60. Korstanje MJ, van Breda Vriesman CJ, van de Staak WJ. Cyclosporine and methotrexate: a dangerous combination. J Am Acad Dermatol. 1990;3(2 Pt 1): 320–1.
61. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, McKendry R, Tesser J, Baker P, Wells G. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate–Cyclosporine Combination Study Group. N Engl J Med. 1995;333(3):137–41.
62. Mazzanti G, Coloni L, De Sabbata G, Paladini G. Methotrexate and cyclosporin combined therapy in severe psoriatic arthritis. A pilot study. Acta Derm Venereol Suppl (Stockh). 1994;186:116–7.
63. Clark CM, Kirby B, Morris AD, Davison S, Zaki I, Emerson R, Saihan EM, Chalmers RJ, Barker JN, Allen BR, Griffiths CE. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol. 1999;141(2):279–82.
64. Kirby B, Harrison PV. Combination low-dose cyclosporin (Neoral) and hydroxyurea for severe recalcitrant psoriasis. Br J Dermatol. 1999;140(1):186–7.
65. Cutolo M. Etanercept improves rheumatoid arthritis partially responsive to methotrexate. Clin Exp Rheumatol. 2001;19(6):626–7.
66. Bankhurst AD. Etanercept and methotrexate combination therapy. Clin Exp Rheumatol. 1999;17(6 Suppl 18):S69–72.
67. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340(4):253–9.
68. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357(9271):1842–7.
69. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody)versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354(9194):1932–9.
70. Kirby B, Marsland AM, Carmichael AJ, Griffiths CE. Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol. 2001;26(1):27–9.
71. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl JMed. 2001;345(15):1098–104.
72. Ameen M, Smith HR, Barker JN. Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis. Clin Exp Dermatol. 2001; 26(6);480–3.
73. Davison SC, Morris-Jones R, Powles AV, Fry L. Change of treatment from cyclosporin to mycophenolate mofetil in severe psoriasis. Br J Dermatol. 2000; 143(2):405–7.